SECONDARY OUTCOMES
SECONDARY
The secondary outcomes are presented in When comparing the number of days with symptoms between the BCG and placebo, there was strong evidence of an interaction between treatment arms and two randomisation strata (age group and presence of comorbidities), which rendered an overall comparison between randomisation groups non-interpretable. Post-hoc subgroup analyses revealed that in the ≥60-year age group, the BCG group had fewer days with symptoms compared with the placebo group (32; 95% CI 0.19 to 0.53; 